title: The Prevalence and Long-Term Outcomes of Extreme Right versus Extreme Left Ventricular Hypertrophic Cardiomyopathy.
abstract: OBJECTIVE
  Extreme left ventricular hypertrophy (LVH) is a known risk factor for sudden cardiac death in hypertrophic cardiomyopathy (HCM). Extreme right ventricular hypertrophy (RVH) is rare, and whether it is linked to a poor outcome is unknown. This study was designed to investigate differences between HCM patients with extreme RVH and those with extreme LVH.
  
  
  METHODS
  Among 2,413 HCM patients, 31 with extreme RVH (maximum right ventricular wall thickness ≥ 10 mm) and 194 with extreme LVH (maximum left ventricular wall thickness ≥ 30 mm) were investigated. The main clinical features and natural history were compared between the 2 groups.
  
  
  RESULTS
  The prevalence of extreme RVH and extreme LVH was 1.3 and 8.0%, respectively. Patients with extreme RVH tended to be younger and female (p < 0.01). Cardiovascular-related mortality and morbidity within 10 years were significantly greater in the extreme RVH group (p < 0.05). Multivariate analysis demonstrated 3 independent predictors for cardiovascular mortality - extreme RVH, left ventricular end-diastolic dimension ≥ 50 mm, and age ≤ 18 years at baseline - and 2 for morbidity - extreme RVH and presyncope.
  
  
  CONCLUSIONS
  Compared with extreme LVH, extreme RVH was quite uncommon in HCM and had a worse prognosis. A right ventricle examination should be performed in routine HCM evaluation.
authors.affiliation: Key Laboratory of Clinical Trial Research in Cardiovascular Drugs, Ministry of Health, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
authors.forename: Xiying
authors.initials: X
authors.lastname: Guo
authors.forename: Chaomei
authors.initials: C
authors.lastname: Fan
authors.forename: Hongyue
authors.initials: H
authors.lastname: Wang
authors.forename: Shihua
authors.initials: S
authors.lastname: Zhao
authors.forename: Fujian
authors.initials: F
authors.lastname: Duan
authors.forename: Zhimin
authors.initials: Z
authors.lastname: Wang
authors.forename: Lirong
authors.initials: L
authors.lastname: Yan
authors.forename: Yinjian
authors.initials: Y
authors.lastname: Yang
authors.forename: Shuoyan
authors.initials: S
authors.lastname: An
authors.forename: Yishi
authors.initials: Y
authors.lastname: Li
mesh_terms: D000293:Adolescent; D000328:Adult; D002312:Cardiomyopathy, Hypertrophic / Q000401:mortality*; D004452:Echocardiography; D015716:Electrocardiography, Ambulatory; D005260:Female; D006352:Heart Ventricles / Q000503:physiopathology*; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000175:diagnosis* / Q000188:drug therapy; D017380:Hypertrophy, Right Ventricular / Q000175:diagnosis* / Q000188:drug therapy*; D053208:Kaplan-Meier Estimate; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D015995:Prevalence; D011379:Prognosis; D016016:Proportional Hazards Models; D055815:Young Adult